ClinicalTrials.gg
RecruitingNCT04769713Updated Jun 2, 2023

Hepatic Hilar Nerve Block Versus Sham in Pain Control During Liver Ablation and TACE Procedures

A Phase 4 interventional study of Hepatic Hilar Nerve Block Needle placement and Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block in Pain Control and Liver Cancer, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-02.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Liver Neoplasms with a site in Canada — 13 open to participants now, 22 under way, 3 of them phase 3. Liver Neoplasms · Canada.

Planned enrollment
34th of 56
80 · median 116
Started
2021
with 1 other
Phase 4
3 of 70
2 open now
Primary completion
2023-06
later than 1 of 21 live
Registered
57th of 70
by date
Lead sponsor
3 of 70
McGill University Health Centre/Research Institute of the McGill University Health Centre

Among the 70 studies in Liver Neoplasms with a site in Canada, this one is the 34th largest by planned enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 4, reaches primary completion later than 1 of the 21 other live ones, and was the 57th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

13 of the 70 studies in Liver Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Liver Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This study is aimed at assessing the effectiveness of a novel liver specific nerve block in improving pain control during painful liver interventional radiology procedures including liver tumoral ablation and trans arterial chemoembolization, two procedures aimed at controlling liver tumors, but that can be associated with significant pain. This novel hepatic specific nerve block was designed by us and initial retrospective results suggests it might help in controlling such liver procedural derived pain. The study was designed to compare the liver block to a sham procedure in a blinded context and to follow the participants over three days post-procedure to asses for pain levels.

Read the detailed description

This is a prospective study. Experienced interventional radiologists in the two McGill University Health Centre study centers (Royal Victoria Hospital and Montreal General Hospital) will perform all procedures:

  • 80 consecutive subjects meeting the eligibility criteria, scheduled for chemoembolization of the liver for primary or secondary liver malignancies OR radiofrequency ablation of the liver for primary or secondary liver malignancies.
  • Consent will be obtained from all patients by an interventional radiologist.
  • All procedures will be performed by a qualified interventional radiology medical doctor (IRMD).
  • Patients who accept to participate and fit the criteria will be randomized to either receive hepatic plexus block or a placebo control procedure, consisting of injection of normal saline.
  • Hepatic hilum plexus nerve block will consist of the ultrasound-guided injection of ropivacaine at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible. In the sham control group, the same location will be targeted, but only normal saline will be injected.
  • A member of the radiology technologists will load the syringe with either ropivacaine or normal saline and the IRMD will thus be blinded to the patient's allocated group.
  • All patients will be offered IV analgesia using midazolam and fentanyl during the procedure at set regular intervals as per our standard regimen.
  • Similar IV analgesics as well as oral analgesics will be provided as per set orders during the recovery period in the post-procedural recovery room (PACU)
  • The patient will be discharged home with standard prescriptions for home analgesics which include routine medication and medication to be used for breakthrough pain. While at home they will be entering pain surveys three times per day for three days.
  • Data will be gathered, stored, and analyzed. The analysis will be stratified into patients who have received chemoembolization and patients who have received radiofrequency ablation.
  • Follow-up of the patient will occur as per routine 4-6 weeks post chemoembolization/radiofrequency ablation to assess the clinical success of the therapeutic procedure (ablation and TACE) and patient satisfaction with pain control.

Subject data collection on the day of the procedure will include demographics, relevant medical history, vital signs before and during the procedure, use of IV analgesics, use of oral analgesics, use of nerve block or sham procedure and visual analogue pain scales at set intervals during hospital stay. Subject data collection while at home will include visual analogue pain scale and self-recording of medication intake.

03

Conditions studied

  • Pain Control
  • Liver Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients referred to the Interventional Radiology department and approved for a chemo-embolization or radiofrequency ablation of malignant primary or secondary liver tumour.
  2. At least 18 y.o.

Exclusion criteria

Exclusion Criteria:

  1. Patients in whom the vascular anatomy prevents safe access to the hepatic hilum or patients in whom general anaesthesia was performed.
  2. Patients who have known allergy to any anaesthetic agent in the regular protocol (fentanyl, midazolam, ropivacaine).
  3. Patients with signs of skin infection at the entry site of the needle used to perform the nerve block
  4. Patients with signs of infection such as fever or acute increase in wight blood cell count.
  5. Patients with uncorrectable abnormal coagulation status ( >1.5 and \< 50000 without use of anticoagulation agents).
  6. Patients with pre-existing conditions, which, in the opinion of the investigator, interfere with the conduct of the study (these reasons will be recorded)
  7. Patients, who are uncooperative, cannot follow instructions, or who are unlikely to comply with follow-up appointments or fill-out the post-procedural pain questionnaires.
  8. Patients with a mental state that may preclude completion of the study procedure or are unable to provide .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Hepatic hilar nerve block in ablation patients

    15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.

    Procedure: Hepatic Hilar Nerve Block Needle placement · Drug: Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block

  • Placebo comparator
    Placebo procedure in ablation patients

    15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.

    Procedure: Hepatic Hilar Nerve Block Needle placement · Drug: Injection of normal saline in the hepatic hilum for the sham procedure

  • Experimental
    Hepatic hilar nerve block in chemoembolization patients

    15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.

    Procedure: Hepatic Hilar Nerve Block Needle placement · Drug: Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block

  • Placebo comparator
    Placebo procedure in chemoembolization patients

    15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the chemoembolization procedure.

    Procedure: Hepatic Hilar Nerve Block Needle placement · Drug: Injection of normal saline in the hepatic hilum for the sham procedure

Interventions

  • ProcedureHepatic Hilar Nerve Block Needle placement

    Placement of a needle within 2cm of the portal vein bifurcation along its anterior surface for injection of nerve block agent (for nerve block) or saline (placebo) under US or CT guidance.

  • DrugInjection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block

    Injection of 15 ml 0.5% Ropivacaine at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.

  • DrugInjection of normal saline in the hepatic hilum for the sham procedure

    15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.

06

What researchers measure

Primary outcomes

  1. Changes in pain after a hepatic hilar nerve block during and immediately after liver ablation

    Visual analog pain score will be compared between patient having received the hepatic hilar nerve block versus those having had a placebo procedure done during the ablation procedure and while in post-anesthetic care unit. Visual analog scales are on a scale of 0-10 with 0 being no pain and 10 the worse pain imaginable.

    Time frame: 1 day

  2. Changes in narcotic use after a hepatic hilar nerve block during and immediately after liver ablation

    Number of mg of narcotics used to control the pain during and immediately after the ablation while in post-anesthetic care unit will be compared between the group having had the hepatic hilar nerve block and those having had the placebo

    Time frame: 1 day

  3. Changes in pain after a hepatic hilar nerve block during and immediately after liver chemoembolization

    Visual analog pain score will be compared between patient having received the hepatic hilar nerve block versus those having had a placebo procedure done during the chemoembolization procedure and while in post-anesthetic care unit. Visual analog scales are on a scale of 0-10 with 0 being no pain and 10 the worse pain imaginable.

    Time frame: 1 day

  4. Changes in narcotic use after a hepatic hilar nerve block during and immediately after liver chemoembolization

    Number of mg of narcotics used to control the pain during and immediately after the chemoembolization while in post-anesthetic care unit will be compared between the group having had the hepatic hilar nerve block and those having had the placebo

    Time frame: 1 day

Secondary outcomes

  1. Changes in pain after a hepatic hilar nerve block in the early days following liver ablation

    Visual analog pain score will be compared between patient having received the hepatic hilar nerve block versus those having had a placebo procedure done up to 3 days post ablation. Visual analog scales are on a scale of 0-10 with 0 being no pain and 10 the worse pain imaginable.

    Time frame: 3 days

  2. Changes in narcotic use after a hepatic hilar nerve block in the early days after liver ablation

    Number of mg of narcotics used to control the pain in the next 3 days after the ablation while in post-anesthetic care unit will be compared between the group having had the hepatic hilar nerve block and those having had the placebo

    Time frame: 3 days

  3. Changes in pain after a hepatic hilar nerve block in the early days following liver chemoembolization

    Visual analog pain score will be compared between patient having received the hepatic hilar nerve block versus those having had a placebo procedure done up to 3 days post chemoembolization. Visual analog scales are on a scale of 0-10 with 0 being no pain and 10 the worse pain imaginable.

    Time frame: 3 days

  4. Changes in narcotic use after a hepatic hilar nerve block in the early days after liver chemoembolization

    Number of mg of narcotics used to control the pain in the next 3 days after the chemoembolization while in post-anesthetic care unit will be compared between the group having had the hepatic hilar nerve block and those having had the placebo

    Time frame: 3 days

  5. Changes in anti-nausea medication use after a hepatic hilar nerve block during and immediately after liver ablation

    Number of mg of anti-nausea medication used to control the pain during and immediately after the ablation while in post-anesthetic care unit will be compared between the group having had the hepatic hilar nerve block and those having had the placebo

    Time frame: 1 day

  6. Changes in anti-nausea medication use after a hepatic hilar nerve block during and immediately after liver chemoembolization

    Number of mg of anti-nausea medication used to control the pain during and immediately after the chemoembolization while in post-anesthetic care unit will be compared between the group having had the hepatic hilar nerve block and those having had the placebo

    Time frame: 1 day

  7. Incidence of complications secondary to performing the hepatic hilar nerve block

    Incidence of complications (graded based on society of interventional radiology complication grading system) will be calculated for the various grades

    Time frame: 4-6 weeks

  8. Differences in disease response post liver tumoral ablation between patients with hepatic hilar nerve block and those with sham procedure

    RECIST criteria scoring system will be used to compare treatment response on CT/MRI 4-6 weeks post liver tumoral ablation in patients having had the hepatic hilar block versus those having had the sham procedure

    Time frame: 4-6 weeks

  9. Differences in disease response post liver tumoral chemoembolization between patients with hepatic hilar nerve block and those with sham procedure

    RECIST criteria scoring system will be used to compare treatment response on CT/MRI 4-6 weeks post liver tumoral chemoembolization in patients having had the hepatic hilar block versus those having had the sham procedure

    Time frame: 4-6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No plan to share individual participant data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Jun 2023, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2020
First posted
Feb 24, 2021
StartActual
Nov 23, 2021
Primary completionEst.
Jun 30, 2023
CompletionEst.
Sep 30, 2023
Last update
Jun 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04769713
Responsible party
Louis-martin Boucher (Assistant Professor Diagnostic Radiology - Interventional Radiology Division, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Feb 24, 2021
Start date
Nov 23, 2021
Primary completion
Jun 30, 2023 (estimated)
Completion
Sep 30, 2023 (estimated)
Last update
Jun 2, 2023

Study contacts

Louis-Martin Boucher, MD/PhD
Contact
lmboucher@yahoo.com
514-934-1934 ext. 44454

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion